Syncytial Virus Inhibitor-1 is a potent and orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion(EC50s of 0.002 μM, 0.004 μM, and 0.002 μM for RSV Long, RSV A2, and RSV B strains, respectively).
Ribavirin-13C5 is intended for use as an internal standard for the quantification of ribavirin by GC- or LC-MS. Ribavirin (T0684) is an antiviral guanosine nucleoside analog.1,2Upon entry into cells,ribavirin is metabolized to an active triphosphate form that induces viral RNA chain termination and inhibits viral polymerases. It reduces replication in a panel of seven RNA and four DNA viruses in Vero cells (EC50s = 2-95 μg/ml).3Ribavirin also reduces replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)in Vero cells (EC50= 109.5 μM).4Aerosol administration of ribavirin (30 mg/kg)reduces mortality in a mouse model of influenza A infection.5Formulations containing ribavirin have been used in the treatment of respiratory syncytial virus (RSV),hepatitis C virus (HCV),and viral hemorrhagic fevers.
RSV-IN-6 (Compound 53) is a specific agent that effectively inhibits the respiratory syncytial virus (RSV) by targeting the M2-1 protein. It shows strong potency, with EC50 values of 4.4 μM and 1.3 μM against RSV-A and RSV-B strains, respectively [1].